ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
18.95
+0.38 (2.05%)
At close: Mar 28, 2025, 4:00 PM
18.67
-0.28 (-1.50%)
After-hours: Mar 28, 2025, 5:16 PM EDT

Company Description

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.

It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors.

The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ArriVent BioPharma, Inc.
ArriVent BioPharma logo
Country United States
Founded 2021
IPO Date Jan 26, 2024
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Zhengbin Yao

Contact Details

Address:
18 Campus Boulevard, Suite 100
Newtown Square, Pennsylvania 19073
United States
Phone 628 277 4836
Website arrivent.com

Stock Details

Ticker Symbol AVBP
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001868279
CUSIP Number 04272N102
ISIN Number US04272N1028
SIC Code 2834

Key Executives

Name Position
Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President and Chief Executive Officer
Dr. Stuart Lutzker M.D., Ph.D. Co-Founder, President of Research and Development and Director
Robin LaChapelle M.A. Co-Founder and Chief Operating Officer
Winston Kung M.B.A. Chief Financial Officer and Treasurer
Yang Wang Ph.D. Chief Technology Officer
James Paul Kastenmayer J.D., Ph.D. General Counsel and Secretary
Meghna Chowdary Senior Vice President of Commercial Strategy

Latest SEC Filings

Date Type Title
Mar 13, 2025 8-K Current Report
Mar 3, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 3, 2025 8-K Current Report
Mar 3, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 3, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Jan 22, 2025 8-K Current Report
Dec 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report